NCT06160440View on ClinicalTrials.gov

The Safety, Tolerability, and Pharmacokinetic Study of SC1011 in Healthy Subjects.

PHASE1CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

June 3, 2021

Primary Completion Date

September 23, 2021

Study Completion Date

February 23, 2022

Conditions
Diopathic Pulmonary FibrosisPulmonary Fibrosis
Interventions
DRUG

SC1011

Each subject in the SAD groups participated in 1 treatment period only and reside at the clinical research unit (CRU) from Day -1 (the day before dosing) to Day 7 (144 hours post dose).

Trial Locations (1)

510000

First Affiliated Hospital of Guang Zhou University of Chinese Medicine, Guangzhou

All Listed Sponsors
lead

Guangzhou JOYO Pharma Co., Ltd

INDUSTRY